Colo-rectal CancerNCT05365412
Clinicopathological Characteristics of Colon Cancer in Young Age
An observational study of Colo-rectal Cancer and Molecular Pathway Deregulation, run by Seoul National University Bundang Hospital at 1 site in South Korea.
Trial summary
A Study on the Characteristics of Colorectal Cancer by Age and sex. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Colo-rectal Cancer, Molecular Pathway Deregulation
- How many people
- 1,400 participants
- Where
- 1 siteSouth Korea
- Study dates
- 1 Jan 2019to Dec 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients treated after being diagnosed with colorectal cancer, and agreed to participate
Who may be able to join
- Patients treated after being diagnosed with colorectal cancer
Who cannot join
- Patients under age of 18 years, or patients who cannot choose whether to participate or not
- Patients who refuse to participate in the study
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
South Korea1 site, 1 recruiting
- Recruiting
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, 463-707
Yonghoon Choi, M.D., +82-31-787-7088, 89796@snubh.org
Nayoung Kim, M.D.,Ph.D.
About this study
A Study on the Characteristics of Colorectal Cancer by Age and sex.
Read the detailed description
The investigators aimed to investigate the prognosis according to sex and age by analyzing the clinical, pathophysiological, and molecular characteristics of colorectal cancer (CRC), and to find the factors influencing the prognosis of CRC.
- Conditions
- Colo-rectal Cancer, Molecular Pathway Deregulation
- Keywords
- colorectal cancer, prognosis, sex difference
- Medical subject headings
- Colonic Neoplasms, Colorectal Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Colorectal cancer group | Patients treated after being diagnosed with colorectal cancer |
What is being measured
The primary outcome is the main question the study is designed to answer.
Survival (overall/disease-specific) according to sex, molecular profiles and sex hormone receptors
Time from diagnosis to death
Measured: From date of enrollment until the date of death from colorectal cancer or from any cause, assessed up to 120 months
Secondary outcomes (1)
Disease-free survival according to sex, molecular profiles and sex hormone receptors
Time from diagnosis to recurrence
Measured: From date of enrollment until the date of first documented recurrence of colorectal cancer, assessed up to 120 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 May 2022
- Study start1 Jan 2019
- Primary completionOct 2026 (estimated)
- Study completionDec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Colo-rectal CancerStudies of the same condition, open and under way.
- More trials run by Seoul National University Bundang HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 1,400 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Seoul National University Bundang Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Nayoung Kim, Seoul National University Bundang Hospital
- Investigators
- Nayoung Kim, MD, PhD, Study chair, Seoul National University Bundang Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05365412
- Sponsor's protocol ID
- B-1901-514-112
- Status last verified
- Apr 2026
- First submitted
- 24 Apr 2022
- Last updated
- 28 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 28 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinicopathological Characteristics of Colon Cancer in Young Age
- ClinicalTrials.gov ID
- NCT05365412
- Acronym / sponsor ID
- B-1901-514-112
- Conditions
- Colo-rectal Cancer, Molecular Pathway Deregulation
- Keywords
- colorectal cancer, prognosis, sex difference
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 1,400 participants (estimated)
- Lead sponsor
- Seoul National University Bundang HospitalUniversity, hospital or other
- Study start
- 1 Jan 2019 (actual)
- Primary completion
- Oct 2026 (estimated)
- Study completion
- Dec 2026 (estimated)
- First posted
- 9 May 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A Study on the Characteristics of Colorectal Cancer by Age and sex.
Detailed description
The investigators aimed to investigate the prognosis according to sex and age by analyzing the clinical, pathophysiological, and molecular characteristics of colorectal cancer (CRC), and to find the factors influencing the prognosis of CRC.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Colorectal cancer group | – | –Patients treated after being diagnosed with colorectal cancer |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients treated after being diagnosed with colorectal cancer, and agreed to participate
Key inclusion criteria (1 listed)
- Patients treated after being diagnosed with colorectal cancer
Key exclusion criteria (2 listed)
- Patients under age of 18 years, or patients who cannot choose whether to participate or not
- Patients who refuse to participate in the study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Survival (overall/disease-specific) according to sex, molecular profiles and sex hormone receptors
Time frame: From date of enrollment until the date of death from colorectal cancer or from any cause, assessed up to 120 months
Time from diagnosis to death
1 secondary outcome
Disease-free survival according to sex, molecular profiles and sex hormone receptors
Time frame: From date of enrollment until the date of first documented recurrence of colorectal cancer, assessed up to 120 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Apr 2026.
- Individual participant dataSharing planned: No
Related trials for Colo-rectal Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
RecruitingPhase 2
Tislelizumab in People With Colorectal Cancer
Colorectal Cancer
Not yet recruitingPhase 2
Alberta Cancer Exercise Dose in Colorectal Cancer
Cancer, Colorectal Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Nayoung Kim, MD, PhD study chair
Seoul National University Bundang Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Colo-rectal Cancer and Molecular Pathway Deregulation, run by Seoul National University Bundang Hospital at 1 site in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 28 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Nayoung Kim, MD, PhD (+82-31-787-7009, nakim49@snu.ac.kr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Survival (overall/disease-specific) according to sex, molecular profiles and sex hormone receptors (time frame: From date of enrollment until the date of death from colorectal cancer or from any cause, assessed up to 120 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Apr 2026.